Annual Reports & Proxies - 9 Meters Biopharma, Inc.

Home
About
Pipeline
Investors
Contact us

Home
About
Pipeline
Investors
Contact us

Annual Reports & Proxies

2018 Annual Report
2019 Annual Report

Email Alerts Print Page

Data may be delayed up to 15 minutes

9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc. (Nasdaq: NMTR) is a rare, orphan and unmet needs focused GI company. The Company is advancing drug candidates for short bowel syndrome and celiac disease. 9 Meters is led by a strong management team with a history of bringing novel therapeutics to market, and the Company owns all global rights to their products, which are backed by more than 150 patents worldwide.

Latest Press Releases

9 Meters Biopharma, Inc. to Participate in BMO Capital Markets' "Hidden Gems in ...more
9 Meters Biopharma, Inc. Amends Definition of Primary Endpoint for Phase 3 Tria ...more
9 Meters Biopharma, Inc. Initiates Phase 1b/2a Clinical Trial in Short Bowel Syn ...more
9 Meters Biopharma, Inc Receives Thorough QT Study Waiver by FDA for Larazotide ...more
9 Meters Biopharma, Inc Announces the Closing of Naia Rare Diseases Acquisition ...more

Latest News

Innovate Biopharmaceuticals Announces Full Year 2019 Financial Results And Strategic And Operational Updates
9 Meters Merger Timeline Affirmed
DDW 2020 Abstracts Accepted
Shareholder Approval Complete to Create 9 Meters Biopharma, Inc.
Innovate and RDD Announce 9 Meters

8480 Honeycutt Road, Suite 120
Raleigh, NC 27615

Tel: +1 (919) 275-1933
Mail: info@9meters.com

Twitter
LinkedIn

© Copyright 2020 | 9 Meters Biopharma Inc. All Rights Reserved | Privacy Policy | Cookies Policy